The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Perturbations of the AKT signaling pathway in human cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pedrero, J. M. G., Carracedo, D. G., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, C. S., & Gonzalez, M. V. (2005) · International Journal of Cancer · doi:10.1002/ijc.20711 · Cited by 235
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,606
Pten is essential for embryonic development and tumour suppression
Cristofano, A. D., Pesce, B., Cordon-Cardo, C., & Pandolfi, P. P. (1998) · Nature Genetics · doi:10.1038/1235 · Cited by 1,516
FOXO transcription factors at the interface between longevity and tumor suppression
Greer, E. L., & Brunet, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209086 · Cited by 1,310
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290
Larue, L., & Bellacosa, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209091 · Cited by 1,228
The Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
PIK3CA is implicated as an oncogene in ovarian cancer
Shayesteh, L., Lu, Y., Kuo, W.-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., & Gray, J. W. (1999) · Nature Genetics · doi:10.1038/5042 · Cited by 1,155
The AMP-activated protein kinase cascade – a unifying system for energy control
Carling, D. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.11.005 · Cited by 1,112
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Role of Akt Signaling in Vascular Homeostasis and Angiogenesis
Shiojima, I., & Walsh, K. (2002) · Circulation Research · doi:10.1161/01.res.0000022200.71892.9f · Cited by 1,012
Dysregulation of the TSC-mTOR pathway in human disease
Inoki, K., Corradetti, M. N., & Guan, K.-L. (2005) · Nature Genetics · doi:10.1038/ng1494 · Cited by 972
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
AKT plays a central role in tumorigenesis
Testa, J. R., & Bellacosa, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211430998 · Cited by 944 · cited 2×
“AKT also directly antagonizes the action of the cell cycle inhibitors p21WAF1 and p27Kip1 by phosphorylating a site located near the nuclear localization signal to induce cytoplasmic retention of these cell cycle inhibitors (reviewed in Testa and Bellacosa, 2001; Bellacosa et al., 2005).”
BackgroundSelf-citationRole of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943
A Retroviral Oncogene, akt , Encoding a Serine-Threonine Kinase Containing an SH2-Like Region
Bellacosa, A., Testa, J. R., Staal, S. P., & Tsichlis, P. N. (1991) · Science · doi:10.1126/science.1833819 · Cited by 939
Self-citationDoes the ribosome translate cancer?
Ruggero, D., & Pandolfi, P. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1015 · Cited by 928
The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway
Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 921
Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression
Liang, J., & Slingerland, J. M. (2003) · Cell Cycle · doi:10.4161/cc.2.4.433 · Cited by 885
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Self-citationAdvances in protein kinase B signalling: AKTion on multiple fronts
Brazil, D. P., Yang, Z.-Z., & Hemmings, B. A. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.03.006 · Cited by 830
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 823
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., & Testa, J. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3636 · Cited by 793
Self-citationPTEN: One Gene, Many Syndromes
Eng, C. (2003) · Human Mutation · doi:10.1002/humu.10257 · Cited by 787
PI 3-kinase, Akt and cell survival
Downward, J. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2004.01.002 · Cited by 783
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 736
Self-citationRole of Akt/protein kinase B in metabolism
Whiteman, E. L., Cho, H., & Birnbaum, M. J. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(02)00662-8 · Cited by 676
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis
Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C., & Pandolfi, P. P. (2004) · Nature Medicine · doi:10.1038/nm1042 · Cited by 586
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Skorski, T., Bellacosa, A., Nieborowska‐Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., et al. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6151 · Cited by 567 · cited 1×
“One example is the aberrant BCR-ABL fusion protein produced by a (9;22) translocation seen in more than 95% of patients with chronic myeloid leukemia (Skorski et al., 1997).”
BackgroundApoptosis defects and chemotherapy resistance: molecular interaction maps and networks
Pommier, Y., Sordet, O., Antony, S., Hayward, R. L., & Kohn, K. W. (2004) · Oncogene · doi:10.1038/sj.onc.1207515 · Cited by 560
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C. L., & Kwiatkowski, D. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17222 · Cited by 538
Lefranc, F., Brotchi, J., & Kiss, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.089 · Cited by 526
Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., & Rosen, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29864 · Cited by 511
The Akt/PKB pathway: molecular target for cancer drug discovery
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 498
Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 486
Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., & Roth, R. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21528 · Cited by 475
Sun, M., Wang, G., Paciga, J. E., Feldman, R. I., Yuan, Z.-Q., Ma, X.-L., Shelley, S. A., Jove, R., Tsichlis, P. N., Nicosia, S. V., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61714-2 · Cited by 454
eIF4E – from translation to transformation
Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L. W., & Sonenberg, N. (2004) · Oncogene · doi:10.1038/sj.onc.1207549 · Cited by 449
Akt-dependent transformation: there is more to growth than just surviving
Plas, D. R., & Thompson, C. B. (2005) · Oncogene · doi:10.1038/sj.onc.1209097 · Cited by 429
Altomare, D. A., Wang, H. Q., Skele, K. L., Rienzo, A. D., Klein-Szanto, A. J., Godwin, A. K., & Testa, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207721 · Cited by 412
Self-citationTransformation of Chicken Cells by the Gene Encoding the Catalytic Subunit of PI 3-Kinase
Chang, H. W., Aoki, M., Fruman, D., Auger, K. R., Bellacosa, A., Tsichlis, P. N., Cantley, L. C., Roberts, T. M., & Vogt, P. K. (1997) · Science · doi:10.1126/science.276.5320.1848 · Cited by 412
The PTEN, Mdm2, p53 tumor suppressor–oncoprotein network
Mayo, L. D., & Donner, D. B. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02166-7 · Cited by 410
Unravelling the activation mechanisms of protein kinase B/Akt
Scheid, M. P., & Woodgett, J. R. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00562-3 · Cited by 390
deGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., & Hidalgo, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0035 · Cited by 387
Yuan, Z. Q., Sun, M., Feldman, R. I., Wang, G., Ma, X.-L., Jiang, C., Coppola, D., Nicosia, S. V., & Cheng, J. Q. (2000) · Oncogene · doi:10.1038/sj.onc.1203598 · Cited by 384
Yang, L., Dan, H. C., Sun, M., Liu, Q., Sun, X.-M., Feldman, R. I., Hamilton, A. D., Polokoff, M., Nicosia, S. V., Herlyn, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0343 · Cited by 371
Akt-regulated pathways in prostate cancer
Majumder, P. K., & Sellers, W. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209096 · Cited by 344
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
Roy, H. K. (2002) · Carcinogenesis · doi:10.1093/carcin/23.1.201 · Cited by 343
Tuberous Sclerosis: from Tubers to mTOR
Kwiatkowski, D. J. (2003) · Annals of Human Genetics · doi:10.1046/j.1469-1809.2003.00012.x · Cited by 339
Ruggeri, B. A., Huang, L., Wood, M., Cheng, J. Q., & Testa, J. R. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2<81::aid-mc1>3.3.co;2-k · Cited by 329
Self-citationBoulay, A., Zumstein-Mecker, S., Stephan, C., Beuvink, I., Zilbermann, F., Haller, R., Tobler, S., Heusser, C., O’Reilly, T., Stolz, B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-3554-2 · Cited by 318
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions
Balsara, B. R. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh226 · Cited by 295
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model
Majumder, P. K., Yeh, J. J., George, D. J., Febbo, P. G., Kum, J., Xue, Q., Bikoff, R., Ma, H., Kantoff, P. W., Golub, T. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1232229100 · Cited by 285
Studies of the molecular mechanisms in the regulation of telomerase activity
LIU, J. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.15.2091 · Cited by 254
The Akt Pathway: Molecular Targets for Anti-Cancer Drug Development
Mitsiades, C., Mitsiades, N., & Koutsilieris, M. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043333032 · Cited by 253
Knobbe, C. B., & Reifenberger, G. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00481.x · Cited by 238
Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease
Astrinidis, A., & Henske, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1209090 · Cited by 209
AKT crystal structure and AKT-specific inhibitors
Kumar, C. C., & Madison, V. (2005) · Oncogene · doi:10.1038/sj.onc.1209087 · Cited by 206
The Akt of translational control
Ruggero, D., & Sonenberg, N. (2005) · Oncogene · doi:10.1038/sj.onc.1209098 · Cited by 196
LKB1, a protein kinase regulating cell proliferation and polarity
Boudeau, J., Sapkota, G., & Alessi, D. R. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00642-2 · Cited by 190
Functional and therapeutic significance of Akt deregulation in malignant melanoma
Robertson, G. P. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1577-9 · Cited by 189
Byun, D., Cho, K., Ryu, B., Lee, M., Park, J., Chae, K., Kim, H., & Chi, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.10962 · Cited by 184
Bjornsti, M.-A., & Houghton, P. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.027 · Cited by 181
Frequent activation of AKT2 kinase in human pancreatic carcinomas
Altomare, D. A., Tanno, S., De Rienzo, A., Klein‐Szanto, A. J., Tanno, S., Skele, K. L., Hoffman, J. P., & Testa, J. R. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10287 · Cited by 174
Self-citationAkt kinases in breast cancer and the results of adjuvant therapy
Stål, O., Pérez-Tenorio, G., Åkerberg, L., Olsson, B., Nordenskjöld, B., Skoog, L., & Rutqvist, L. E. (2003) · Breast Cancer Research · doi:10.1186/bcr569 · Cited by 167
Altomare, D. A., You, H., Xiao, G.-H., Ramos-Nino, M. E., Skele, K. L., De Rienzo, A., Jhanwar, S. C., Mossman, B. T., Kane, A. B., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208744 · Cited by 158
Self-citationBacus, S. S., Altomare, D. A., Lyass, L., Chin, D. M., Farrell, M. P., Gurova, K. V., Gudkov, A. V., & Testa, J. R. (2002) · Oncogene · doi:10.1038/sj.onc.1205438 · Cited by 157
Self-citationTerakawa, N., Kanamori, Y., & Yoshida, S. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100203 · Cited by 151
Cheng, J. Q., Altomare, D. A., Klein, M. A., Lee, W.-C., Kruh, G. D., Lissy, N. A., & Testa, J. R. (1997) · Oncogene · doi:10.1038/sj.onc.1201121 · Cited by 148
Self-citationThant, A. A., Nawa, A., Kikkawa, F., Ichigotani, Y., Zhang, Y., Sein, T. T., Amin, A. R. M. R., & Hamaguchi, M. (2000) · Clinical & Experimental Metastasis · doi:10.1023/a:1010921730952 · Cited by 146
Miwa, W., Yasuda, J., Murakami, Y., Yashima, K., Sugano, K., Sekine, T., Kono, A., Egawa, S., Yamaguchi, K. D., Hayashizaki, Y., et al. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1280 · Cited by 123
Class reunion: PTEN joins the nuclear crew
Lian, Z., & Cristofano, A. D. (2005) · Oncogene · doi:10.1038/sj.onc.1209089 · Cited by 105
PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells
Sun, S., & Steinberg, B. M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-7-1651 · Cited by 101 · cited 1×
“…mechanisms include activation of PI3K due to autocrine or paracrine stimulation of receptor tyrosine kinases (Yuan et al., 2000; Tanno et al., 2001; Sun and Steinberg, 2002), overexpression of growth factor receptors such as the epidermal growth factor receptor in glioblastoma multiforme (Schlegel…”
BackgroundJücker, M., Südel, K. M., Horn, S., Sickel, M. J., Wegner, W., Fiedler, W., & Feldman, R. A. (2002) · Leukemia · doi:10.1038/sj.leu.2402484 · Cited by 97
Amplification of 19q13.1–q13.2 sequences in ovarian cancer
Thompson, F. H., Nelson, M. A., Trent, J. M., Guan, X., Liu, Y., Yang, J.-M., Emerson, J., Adair, L., Wymer, J. A., Balfour, C. A., et al. (1996) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(95)00248-0 · Cited by 96
Regulation of Sensitivity to TRAIL by the PTEN Tumor Suppressor
Whang, Y. E., Yuan, X., Liu, Y., Majumder, S., & Lewis, T. D. (2004) · Vitamins and hormones · doi:10.1016/s0083-6729(04)67021-x · Cited by 51
p73-Mediated Chemosensitivity: A Preferential Target of Oncogenic Mutant p53
Strano, S., & Blandino, G. (2003) · Cell Cycle · doi:10.4161/cc.2.4.426 · Cited by 37
Zuev, Y. S. (2002) · International Polymer Science and Technology · doi:10.1177/0307174x0202900615 · Cited by 5
Cited by
AKT/PKB Signaling: Navigating the Network
Manning, B. D., & Toker, A. (2017) · Cell · doi:10.1016/j.cell.2017.04.001 · Cited by 3,772
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
FOXO transcription factors at the interface between longevity and tumor suppression
Greer, E. L., & Brunet, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209086 · Cited by 1,310
Metadata
- Authors
- Altomare, D. A., & Testa, J. R.
- Venue
- Oncogene
- Published
- 2005-11-14
- Volume
- 24
- Issue
- 50
- Pages
- 7455-7464
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1966133006
- Cited by
- 1,329
- References
- 88
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.